Japan’s Toshiba Corp. announced on November 25th that it will launch an empirical trial of a new early-diagnosis cancer technology it has developed in 2020, which is expected to detect 13 types of cancer from a drop of blood with a accuracy of 99%, and strive to be practical within a few years.
According to reports, the technology is based on a joint study by Tokyo Medical University and the National Cancer Research Center of Japan, by examining the molecular species and concentration of “micrornanucleic acid” secreted in the blood, it can detect 13 types of cancer such as breast cancer, pancreatic cancer, esophageal cancer, stomach cancer, colorectal cancer and so on at an extremely early stage. When put into practice, the technology is expected to improve patient survival.
Reported that, at present, Toshiba has successfully developed a small chip and small instruments that can detect RNA in a short period of time, said to be able to detect results within 2 hours, the price can also be controlled at 20,000 yen (about 1294 yuan).
In addition to Toshiba, a number of companies are also actively studying this technology, and strive to be as early as possible into practical, but Toshiba said its technology “in terms of accuracy, time, cost advantages.”
Toshiba, which now positions its healthcare business as one of its growth areas, hopes to accelerate the practical use of the new technology after passing empirical tests.